G1 Therapeutics, Inc. GTHX
7.16 0.00 (+0.00%)
Sep 17, 2024, 3:56 PM EDT
7.14 Day range 7.16
52-week range unavailable
News
globenewswire.com Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer - Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash…
globenewswire.com GTHX SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Tender Offer of G1 Therapeutics, Inc. NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS…
globenewswire.com SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GTHX, PETQ on Behalf of Shareholders NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or…
zacks.com G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates G1 Therapeutics (GTHX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.14 per share a year ago.
globenewswire.com G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights - Entered into Definitive Merger Agreement to be Acquired by Pharmacosmos; Transaction Expected to Close in Late Third Quarter 2024 - - Achieved $15.8 Million in Net Revenue from Sales of COSELA®…
prnewswire.com Shareholder Alert: Ademi LLP investigates whether G1 Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders MILWAUKEE , Aug. 7, 2024 /PRNewswire/ -- Ademi LLP is investigating GI (Nasdaq: GTHX) for possible breaches of fiduciary duty and other violations of law in its transaction with Pharmacosmos. Click…
investorplace.com Why Is G1 Therapeutics (GTHX) Stock Up 66% Today? G1 Therapeutics (NASDAQ: GTHX ) stock is rocketing higher on Wednesday after the company announced an acquisition deal with Pharmacosmos Group. Pharmacosmos Group has agreed to acquire all…
globenewswire.com Pharmacosmos Group to Acquire G1 Therapeutics - Business Combination Expected to Provide Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Optimal Access to G1's COSELA® (trilaciclib), the First and Only Proactive Multilineage…
globenewswire.com G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., Aug. 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options…
globenewswire.com G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 RESEARCH TRIANGLE PARK, N.C., July 25, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a…
investorplace.com G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025 While small-capitalization biotechnology firms bring much potential to the table, they also represent a source of unpredictability. Nevertheless, for risk-takers, oncology specialist G1 Therapeutics…
investorplace.com Biotech Bombshell: G1 Therapeutics Stock Is Too Much of a Gamble Biotechnology stocks can be thrilling and profitable when you're on the winning side of a trade. G1 Therapeutics' (NASDAQ: GTHX ) started hot, but then the bottom fell out after an unfortunate…
globenewswire.com G1 Therapeutics Added to the Russell 2000® and 3000® Indexes RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company has been added to the…
seekingalpha.com G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty G1 Therapeutics, Inc. faces a setback as a trial for triple-negative breast cancer fails to improve survival, leading to a significant market selloff. The company's main drug, trilaciclib, shows…
benzinga.com Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday? Shares of G1 Therapeutics Inc GTHX are trading lower after the company released topline results from the final OS analysis of its Phase 3 PRESERVE 2 trial evaluating the efficacy and safety of…
investorplace.com Why Is G1 Therapeutics (GTHX) Stock Down 56% Today? G1 Therapeutics (NASDAQ: GTHX ) stock is falling hard on Monday after the company provided investors with an update on its Phase 3 clinical trial of trilaciclib as a breast cancer treatment. G1…
reuters.com G1 Therapeutics' breast cancer drug fails in late-stage trial G1 Therapeutics said on Monday its drug for a rare, aggressive form of breast cancer did not meet the main goal of overall survival in a late-stage trial.
globenewswire.com G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC) G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negativ
globenewswire.com G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) RESEARCH TRIANGLE PARK, N.C., June 05, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options…
benzinga.com Earnings Scheduled For February 28, 2024 Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion.
benzinga.com Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance.
benzinga.com Why ZoomInfo Technologies Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket Shares of ZoomInfo Technologies Inc. (NASDAQ: ZI) rose sharply in today’s pre-market trading as the company reported stronger-than-expected fourth-quarter financial results.
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session Gainers- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session - benzinga.com Earnings Scheduled For November 1, 2023 Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
- benzinga.com Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session Gainers
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023 - benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 275 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 283 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 150 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday During Monday's session, 201 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 149 companies reached new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's trading, 103 companies set new 52-week lows.
- benzinga.com Earnings Scheduled For August 2, 2023 Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (NYSE:EDV) is estimated to report quarterly earnings at $0.37 per share on revenue of $784.53 million.
- benzinga.com Stocks That Hit 52-Week Lows On Friday Friday's session saw 59 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 54 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 345 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday Monday's session saw 114 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 220 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 469 companies hit new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 175 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 497 companies set new 52-week lows.
benzinga.com Earnings Scheduled For March 1, 2023 Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
- benzinga.com Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday Gainers Starry Group Holdings, Inc. (NYSE: STRY) rose 55.6% to close at $0.28 on Wednesday after reporting Q3 results.
- benzinga.com Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session Gainers Starry Group Holdings, Inc. (NYSE: STRY) gained 56% to $0.2808 after reporting Q3 results.
- benzinga.com Earnings Scheduled For November 2, 2022 Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.